Prima BioMed Awarded Japanese Patent for CVac(TM)
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwired) -- 04/17/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") is pleased to announce that it has been granted a patent from the Japanese Patent Office that protects methods used in the manufacture of CVac. The method of use claims secured in patent number 5192020 entitled "Use of mannose receptor-bearing antigen presenting cells for the manufacture of medicament for eliciting cytotoxic T cell response to antigen" provide for the treatment of patients with dendritic cells that have been pulsed with mannan fusion protein (M-FP) conjugated to an antigen, including but not limited to mucin 1.
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.04.2013 - 11:00 Uhr
Sprache: Deutsch
News-ID 249848
Anzahl Zeichen: 0
contact information:
Town:
SYDNEY, AUSTRALIA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 160 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prima BioMed Awarded Japanese Patent for CVac(TM)"
steht unter der journalistisch-redaktionellen Verantwortung von
Prima BioMed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
